Abstract 64P
Background
Tumor associated macrophages (TAMs) are highly abundant immune cells present within the microenvironment of multiple tumor types. TAMs with a type 2 (M2)-like phenotype generally associate with poor prognosis and resistance against immunotherapy. In fact, we observed high frequencies of M2-like TAMs relative to those of CD8+ T cells according to gene expression analyses in multiple tumor types. In this study, we aim to engineer CD8+ T cells that resist M2-like macrophage-mediated suppression.
Methods
First, we have set up an in vitro co-culture model of human autologous M2-like macrophages and CD8+ T cells that yields T cell suppression. To this end, we have polarized in vitro monocytes from healthy donors into M2-like macrophages using a cytokine cocktail, after which we have optimized critical parameters, such as type of T cell stimulation, co-culture duration and the ratio between the two cell types.
Results
With this model, we have demonstrated that M2-like macrophages from multiple donors, when co-cultured with anti-CD3/CD28 antibody-stimulated autologous CD8+ T cells for 6 days, suppressed T cell proliferation by 50%. In a second step, we have adapted this model to a CRISPR-Cas9 gene editing-based approach: single guide RNA lentiviral infection with Cas9 electroporation (SLICE). We have successfully performed single gene editing, and are currently editing CD8+ T cells with gene libraries targeting kinases.
Conclusions
Taken together, we present a robust in vitro model of M2-like macrophage-mediated suppression of CD8+ T cells which enables the identification of genes that contribute to suppression-resistant CD8+ T cells. The making of such synthetic T cells is anticipated to aid the anti-tumor efficacy of adoptive T cell therapy.
Legal entity responsible for the study
Erasmus MC.
Funding
KWF Kankerbestrijding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract